Daly James M 4
4 · MADRIGAL PHARMACEUTICALS, INC. · Filed Feb 28, 2025
Insider Transaction Report
Form 4
Daly James M
Director
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2025-02-27−9,470→ 0 totalExercise: $65.06Exp: 2025-06-16→ Common Stock (9,470 underlying) - Exercise/Conversion
Common Stock
2025-02-27$111.06/sh+6,000$666,360→ 17,382 total - Sale
Common Stock
2025-02-27$348.94/sh−770$268,686→ 1,912 total - Exercise/Conversion
Common Stock
2025-02-27$65.06/sh+9,470$616,118→ 11,382 total - Sale
Common Stock
2025-02-27$346.90/sh−398$138,067→ 16,984 total - Sale
Common Stock
2025-02-27$347.39/sh−14,302$4,968,372→ 2,682 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-02-27−6,000→ 0 totalExercise: $111.06Exp: 2025-06-17→ Common Stock (6,000 underlying)
Footnotes (4)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $346.34 to $347.18, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $347.36 to $348.225, inclusive.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $348.73 to $349.705, inclusive.
- [F4]The shares underlying this option are fully vested and exercisable.